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Humanin G (HNG) protects age-related macular
degeneration (AMD) transmitochondrial ARPE-19
cybrids from mitochondrial and cellular damage
Sonali Nashine1, Pinchas Cohen2, Marilyn Chwa1, Stephanie Lu1,3, Anthony B Nesburn1,4, Baruch D Kuppermann1 and
M Cristina Kenney*,1,5
Age-related macular degeneration (AMD) ranks third among the leading causes of visual impairment with a blindness prevalence
rate of 8.7%. Despite several treatment regimens, such as anti-angiogenic drugs, laser therapy, and vitamin supplementation, being
available for wet AMD, to date there are no FDA-approved therapies for dry AMD. Substantial evidence implicates mitochondrial
damage and retinal pigment epithelium (RPE) cell death in the pathogenesis of AMD. However, the effects of AMD mitochondria
and Humanin G (HNG), a more potent variant of the mitochondrial-derived peptide (MDP) Humanin, on retinal cell survival have not
been elucidated. In this study, we characterized mitochondrial and cellular damage in transmitochondrial cybrid cell lines that
contain identical nuclei but possess mitochondria from either AMD or age-matched normal (Older-normal (NL)) subjects. AMD
cybrids showed (1) reduced levels of cell viability, lower mtDNA copy numbers, and downregulation of mitochondrial replication/
transcription genes and antioxidant enzyme genes; and (2) elevated levels of genes related to apoptosis, autophagy and ER-stress
along with increased mtDNA fragmentation and higher susceptibility to amyloid-β-induced toxicity compared to NL cybrids. In
AMD cybrids, HNG protected the AMD mitochondria, reduced pro-apoptosis gene and protein levels, upregulated gp130
(a component of the HN receptor complex), and increased the protection against amyloid-β-induced damage. In summary, in
cybrids, damaged AMD mitochondria mediate cell death that can be reversed by HNG treatment. Our results also provide evidence
of Humanin playing a pivotal role in protecting cells with AMD mitochondria. In the future, it may be possible that AMD patient’s
blood samples containing damaged mitochondria may be useful as biomarkers for this condition. In conclusion, HNG may be a
potential therapeutic target for treatment of dry AMD, a debilitating eye disease that currently has no available treatment. Further
studies are needed to establish HNG as a viable mitochondria-targeting therapy for dry AMD.
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Age-related macular degeneration (AMD), a devastating retinal
disease, is a leading cause of irreversible blindnessworldwide.1
Pathologically, early AMD manifests with formation of drusen
deposits between the retinal pigment epithelium (RPE) and
Bruch’s membrane. Advanced stages manifest with significant
RPE degeneration, along with photoreceptor loss (geographic
atrophy), and/or choroidal neovascularization.2
Several effective anti-VEGF drugs are available to treat the
wet form of AMD.3 For the dry form of AMD, administration of
various antioxidant formulations is recommended but there
are no FDA-approved drugs.4
Retina is one of the highest energy demanding and oxygen-
consuming tissues of the human body, relying on oxidative
mitochondrial metabolism for ATP formation.5 Mitochondrial
DNA (mtDNA) is a 16.5 kb, circular, double-stranded molecule
comprised of 37 genes that code for 2 ribosomal RNAs, 22
transfer RNAs, and 13 proteins, which play key roles in the
electron transport chain and oxidative phosphorylation.6
mtDNA is particularly susceptible to oxidative damage
because of its poor DNA repair capacity. Any mtDNA damage
causes perturbations in energy metabolism, leading to
oxidative stress, depletion of antioxidants and eventual RPE
cell death. A large body of literature has linked mitochondrial
dysfunction and resulting RPE cell death to the development
and progression of AMD, glaucoma, diabetic retinopathy.7–12
Recent studies have identified mitochondrial-derived pep-
tides (MDPs) that are coded from the mtDNA.13–15 The first
MDP, Humanin, is a 24-amino acid polypeptide that was
discovered while screening cDNA libraries from brain of a
patient with Familial Alzheimer’s Disease. Humanin has a
molecular weight of 2687.26 Da and is encoded from a small
open reading frame within the 16S ribosomal RNA gene, MT-
RNR2, of the mitochondrial genome.16 Humanin is cytopro-
tective against amyloid-β induced toxicity in neuronal cells
both in vitro and in vivo,17,18 against cerebral ischemia and
cardiac damage in mouse models,19,20 and in numerous
neurodegenerative disease models for Alzheimer’s disease,
Huntington’s disease, and Prion diseases.21–23 Moreover,
Humanin rescues primary RPE cells from oxidative damage
and subsequent death in vitro.24 Each of the 24 amino acids in
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the Humanin peptide have a specific function. Serine at
position 14 confers neuroprotection,25 but its substitution with
glycine generates a variant called Humanin G (HNG) that is
1000-fold more potent than its parent analog Humanin.16 HNG
is known to protect against cell death by preventing
mitochondrial dysfunction.26
Numerous studies highlight the cytoprotective role of HNG
against Alzheimer’s disease and cancer,26,27 but none have
shed light on the role of HNG in protecting AMD mitochondria
or AMD ARPE-19 transmitochondrial cybrid cells. Our cybrids
were created by fusing human ARPE-19 Rho0 (lacking
mtDNA) cells with mitochondria from either AMD or age-
matched normal subjects. Previously we have shown that
despite all cell lines having identical nuclei, cybrids with AMD
mitochondria express significantly different levels of comple-
ment RNA and proteins compared to normal cybrids.28 These
changes can be attributed to variations in mtDNA, since all
cybrids had similar nuclear content andwere created using the
sameRho0 ARPE-19 cells. Furthermore, our previous studies
have shown that mtDNA variants in cybrids can also affect the
expression of inflammation, angiogenesis, and signaling
genes.29
The present study demonstrates that cybrids containing
AMD mitochondria have increased mtDNA fragmentation,
impaired expression of mitochondrial replication/transcription
genes, upregulation of pro-apoptotic genes and proteins,
along with higher ROS levels and diminished cell viability
compared to normal cybrids. Exposure to HNG reverses these
events and protects the AMD mitochondria, promoting
increased cellular longevity. Mechanistically, our results
suggest that exogenous HNG acts via both intracellular
(BAX) and extracellular (gp130) pathways and that retrograde
signaling from AMD mitochondria to RPE cell nuclei
contributes significantly to retinal cell death.
Results
AMD cybrids have damaged mitochondria. To character-
ize mtDNA damage in AMD cybrids, the mtDNA copy
Figure 1 AMD cybrids have dysfunctional mitochondria. (a) AMD cybrids showed significantly reduced mitochondrial DNA (mtDNA) copy number compared to the age-
matched normal cybrids (n= 5, P= 0.007). (b) AMD cybrids had lower expression levels of mitochondria replication and transcription genes. The AMD cybrids showed reduced
expression of TFAM (90.1% decrease, P= 0.04, n= 5), POLG (78.1% decrease, P= 0.03, n= 5), POLRMT (53.8% decrease, P= 0.03, n= 5), and TFB2M (97.6% decrease,
P= 0.03, n= 5) compared to normal cybrids (Supplementary Table S5). (c) Representative images of confocal microscopy showing diminished mtGFP staining throughout the
cytoplasm in AMD cybrids compared to normal cybrids (Scale bar = 20 μm). (d) Quantitation of the 1C images showed that AMD cybrids had a 54% (P= 0.04, n= 4) decrease
in mtGFP fluorescence compared to normal cybrids, suggesting lower numbers of AMD mitochondria. (e) AMD cybrids showed higher number of mtDNA lesions within the
503–2484 bps region compared to normal cybrids (P= 0.04, n= 5). Data are represented as mean±S.E.M., normalized to normal cybrids (assigned value of 1). The endpoint
for all experiments was 72 h
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numbers, expression levels of mt replication/transcription
genes, mtGFP staining, and mtDNA fragmentation in normal
and AMD cybrids were examined. Our results showed 31%
reduction in mtDNA copy numbers in AMD cybrids
(0.69±0.16 (mean±S.E.M.) arbitrary units (a.u.)) compared
to normal cybrids (1± 0.16 a.u., P=0.007) (Figure 1a). AMD
cybrids showed decreased gene expression levels of TFAM
(90.1%), POLG (78.1%), POLRMT (53.8%), and TFB2M
(97.6%), compared to normal cybrids (Po0.05) (Figure 1b
and Supplementary Table S5). When exposed to CellLight
mt-GFP stain, AMD cybrids (0.46±0.05 a.u.) exhibited 54%
decreased fluorescence compared to normal (1±0.2 a.u.,
P= 0.04) (Figures 1c and d). Analyses of the 503-2484 bps
mtDNA regions showed 120% higher numbers of mtDNA
lesions in AMD cybrids (2.2±0.34 a.u.) compared to normal
(1± 0.32 a.u., P=0.04) (Figure 1e). Overall, these results
suggest that mitochondria from AMD patients have signifi-
cantly higher levels of mtDNA damage with impaired
replication and transcription.
AMD cybrids show decreased cellular viability and
higher mt ROS production. Cell viability levels of normal
and AMD cybrids were measured using both the MTT and
Trypan blue dye exclusion assays. Using the MTT assay,
AMD cybrids demonstrated significantly decreased cell
viability at 24 h (18%), 48 h (17%), and 72 h (18%) compared
to normal cybrids (Po0.05). At 96 h, normal and AMD cybrid
values were similar to each other (P=0.98) (Figure 2a). The
trypan blue assay results at 72 h showed 11% decrease in
cell viability in AMD cybrids compared to normal (P=0.002,
Figure 2b). The mitochondrial superoxide levels, as mea-
sured by the MitoSOX assay, were 80% higher in AMD
cybrids compared to normal (P= 0.003, Figure 2c)
(Supplementary Table S4). These findings demonstrate
increased oxidative stress in AMD cybrids and suggest that
the AMD mitochondria cannot support cell growth at the rates
seen in normal cybrids.
AMD cybrids show differential expression of apoptosis,
autophagy, ER stress, and antioxidant markers. To
determine if AMD mitochondria affect expression of cell
death and cell stress markers, qRT-PCR and western blotting
were performed. Compared to normal cybrids, the AMD
cybrids showed significant upregulation of apoptosis genes
(Figure 3a): BAX (30.8%), Caspase-3 (125.7%) Caspase-7
(181.3%), and Caspase-9 (82.8%); autophagy genes
(Figure 3c): ATG5 (54.4%), ATG12 (130.5%), LAMP2
(184.5%), LC3B (513.8%), PARK2 (326.3%), and MFN1
(741.2%); and ER stress genes (Figure 3e): DDIT3 (633.9%),
eIF2 (66.2%), and XBP1 (220.2%). Furthermore, AMD
cybrids showed downregulation of antioxidant genes, PRDX3
(18.8%) and SOD2 (23.1%) compared to normal (Figure 3g)
(Po0.05) (Supplementary Table S5). Western blot analyses
showed that the AMD cybrids had significantly higher protein
levels of Cleaved Caspase-3 (120.4%, Figure 3b), LC3B
(49.1%, Figure 3d), and DDIT3 (261%, Figure 3f); and 38%
reduced SOD2 protein levels in AMD cybrids (Figure 3h)
(Po0.05) (Supplementary Table S6).
Since all cybrids have identical nuclei, these results suggest
that AMD mitochondria may mediate cell death/stress by
upregulation of nuclear-encoded apoptosis, autophagy, and
ER stress genes and downregulation of antioxidant genes.
HNG reduces mtDNA-mediated apoptosis in AMD
cybrids. To test the effects of exogenous HNG (3.2 μM) on
the numbers of live and apoptotic cells, cybrids were treated
with YO-PRO-1 and propidium iodide stains, followed by flow
cytometry analyses at 72 h. Figures 4a–d show representa-
tive profiles of untreated- and HNG-treated normal cybrids
and AMD cybrids. Untreated-AMD cybrids had 379%
increase in apoptotic cells (Figure 4e) and 36% decrease in
live cells (Figure 4f) compared to untreated-normal cybrids
(Po0.05). HNG drastically reduced the apoptotic cell number
by 46.13% (Figure 4e) and increased the number of live
cells by 34.37% (Figure 4f) in HNG-treated AMD cybrids
Figure 2 AMD cybrids show decreased cellular viability and higher mitochondrial (mt) ROS production. (a) The MTTassay demonstrated reduced numbers of viable cells in
AMD cybrid cultures (24 h, 18% decline, P= 0.03, n= 4); (48 h, 17% decline, P= 0.03, n= 4); (72 h, 18% decline, Po0.001, n= 4). At 96 h, the cell numbers in both normal
and AMD cybrids declined and were similar to each other (P= 0.98, n= 4) (Supplementary Table S4). (b) When measured with Trypan blue dye exclusion assay, cell viability at
72 h declined significantly (11%, P= 0.002, n= 5) in AMD cybrids compared to normal cybrids (Supplementary Table S4). (c) MitoSOX assay at 72 h demonstrated higher
mitochondrial ROS production in AMD cybrids compared to normal cybrids (80%, P= 0.003, n= 5) (Supplementary Table S4). Data are represented as mean± S.E.M.,
normalized to normal cybrids (assigned value of 1). The endpoint for all experiments was 72 h
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compared to untreated-AMD cybrids (Po0.05)
(Supplementary Table S7). No differences in either the
apoptotic or live cell number were observed between
untreated- and HNG-treated normal cybrids. Therefore, the
AMD cybrids have higher levels of apoptotic and dead cells
compared to cybrids with normal mitochondria. However,
treatment with HNG can protect from apoptosis and elevate
the levels of viable, healthy cells in AMD cybrids.
In AMD cybrids, HNG treatment caused a significant
decrease in the gene expression of apoptotic markers such
as BAX (49.4%), BCL2L13 (23.69%), Caspase-3 (25.85%),
Caspase-7 (39.83%), and Caspase-9 (29.9%) compared to
untreated-AMD cybrids (Po0.05) (Figures 5a–e,
Supplementary Table S8). No differenceswere found between
untreated- versus HNG-treated normal cybrids. In summary,
HNG reduced apoptosis in AMD cybrids, thereby highlighting
its protective role in cybrids containing AMD mitochondria.
HNG modulates the protein levels of BAX, gp130
receptor, and Phospho-JAK2 in AMD cybrids. To assess
mechanisms by which HNG protects AMD cybrids, the
protein levels of BAX (acts intracellularly), gp130 (a trans-
membrane glycoprotein and cell surface receptor), and
phosphorylated (Phospho)-JAK2 (a signaling molecule and
a marker of activated JAK) were compared. As shown in
Figure 6a, BAX was significantly elevated (145.9%, P=0.04)
in untreated AMD cybrids compared to untreated normal
cybrids. In AMD cybrids, HNG decreased BAX protein levels
by 74.42% compared to untreated-AMD cybrids (P=0.002)
(Supplementary Table S9).
Untreated-AMD cybrids showed 44.4% decrease in gp130
(P= 0.03, Figure 6b) and 20.25% decrease in Phospho-JAK2
(P= 0.009, Figure 6c), compared to untreated-normal cybrids.
HNG treatment increased gp130 by 61.87% (P=0.007,
Figure 6b) and Phospho-JAK2 by 48.05% (P=0.003,
Figure 6c) in AMD cybrids compared to untreated-AMD
cybrids. The gp130 protein levels were unchanged
(Figure 6b) and the Phospho-JAK2 protein levels were
32.57% lower (P= 0.003, Figure 6c) in HNG-treated AMD
cybrids compared to HNG-treated normal cybrids
(Supplementary Table S9).
Figure 3 AMD cybrids showed differential expression levels of apoptosis, autophagy, ER stress, and antioxidant genes at 72 h. To examine the involvement of molecular/
cellular pathways in mtDNA-mediated cell death, the gene expression profiles of apoptosis, autophagy, ER stress, and antioxidant markers were measured. (a,c,e,g) Using qRT-
PCR analyses, the AMD cybrids showed upregulation of Apoptosis genes (a): BAX (30.8%, P= 0.02, n= 5), Caspase-3 (125.7%, P= 0.03, n= 4), Caspase-7 (181.3%,
P= 0.03, n= 4–5), Caspase-9 (82.8%, Po0.001, n= 4–5); Autophagy genes (c): ATG5 (54.4%, P= 0.02, n= 4), ATG12 (130.5%, P= 0.03, n= 4), LAMP2 (184.5%,
Po0.001, n= 4), LC3B (513.8%, P= 0.01, n= 4), PARK2 (326.3%, Po0.001, n= 4), MFN1 (741.2%, P= 0.02, n= 5); and ER stress genes (e): DDIT3 (633.9%, P= 0.006,
n= 4), eIF2α (66.2%, P= 0.03, n= 4), XBP1 (220.2%, P= 0.005, n= 4) compared to normal cybrids. AMD cybrids showed downregulation of antioxidant genes (g), PRDX3
(18.8%, P= 0.02, n= 5) and SOD2 (23.1%, P= 0.04, n= 3) in AMD cybrids (Supplementary Table S5). (b,d,f,h) Western blot analyses showed upregulated protein
levels of Cleaved-Caspase-3 (120.4%, P= 0.007, n= 5; b), LC3B (49.1%, P= 0.04, n= 4; d), DDIT3 (261%, P= 0.01, n= 5; f), and downregulation of SOD2 (38%, P= 0.01,
n= 5; h) in AMD cybrids (Supplementary Table S6). Data are represented as mean±S.E.M., normalized to normal cybrids (assigned value of 1) . The endpoint for all
experiments was 72 h
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These results demonstrate that: (1) AMD cybrids have
altered BAX and gp130 protein levels, which can be restored
to normal levels with HNG treatment, and (2) AMD cybrids
have reduced Phospho-JAK levels, and HNG treatment
activates JAK, thereby signaling the transcription of down-
stream protective genes and mediating cytoprotection.
HNG reduces amyloid β-induced and mtDNA-mediated
cell stress in AMD cybrids. To determine if HNG protected
against amyloid β-induced cell stress, the normal and AMD
cybrids were treated with either HNG alone, amyloid-β1–42
(active form) or amyloid-β42–1 (inactive scrambled control)
peptides alone or a combination of HNG plus amyloid-β. Cell
viability was measured using the MTT assay.
Figure 7a demonstrates that HNG can protect normal
cybrids against the cytotoxic effects of amyloid-β. Normal
cybrids treated with amyloid-β1–42 (active form, bar 2) showed
reduced cell viability compared to untreated-normal
(35%, Po0.001, bar 1) and amyloid-β42-1-treated (scrambled
form) normal cybrids (31.25%, Po0.05, bar 3). Untreated-
normal cybrids (bar 1) had similar levels of cell viability as
amyloid-β42-1-treated (scrambled form, bar 3) and HNG-
treated normal cybrids (bar 4). HNG increased cell viability
by 35.94% in amyloid-β1–42-treated normal cybrids (bar 5)
compared to the amyloid-β1–42-treated normal group
(Po0.05, bar 2) (Supplementary Table 10 A).
HNG can also protect AMD cybrids against the cytotoxic
effects of amyloid-β (Figure 7b). The amyloid-β1–42-treated
AMD cybrids (active form, bar 2) showed 41.8% reduced cell
viability compared to untreated-AMD (Po0.05, bar 1) and
94.9% reduction compared to amyloid-β42-1-treated
(scrambled form) AMD cybrids (Po0.01, bar 3). Untreated-
AMD cybrids (bar 1) had similar levels of cell viability as
amyloid-β42-1-treated (scrambled form, bar 3). HNG-treated
AMD (bar 4) cybrids had 42.4% increased cell viability
compared to untreated-AMD cybrids (bar 1, Po0.05). AMD
Figure 4 HNG reduces mitochondrial DNA-mediated apoptosis in cybrids. Flow cytometric analyses used YO-PRO1 and PI stains to identify apoptotic cells, live cells, and
dead cells in AMD and normal cybrids treated with 3.2 μM HNG for 72 h. Flow cytometry scatter plots of untreated normal (a) and untreated-AMD (c) cybrids along with
HNG-treated normal (b) and HNG-treated AMD (d) cybrids are shown. The untreated-AMD cybrids had a 379% increase (P= 0.001, n= 3–4) in apoptotic cells (e) and a 36%
decrease (P= 0.0009, n= 3–4) in live cells (f), compared to untreated normal cybrids. HNG treatment significantly decreased apoptotic cell numbers by 46.13% (P= 0.02,
n= 3–4) in AMD cybrids compared to untreated AMD cybrids (e). No differences in the number of apoptotic cells and live cells were observed between untreated-normal and
HNG-treated normal cybrids (Supplementary Table S7). Data are represented as mean± S.E.M., normalized to untreated-normal cybrids (assigned value of 1). The endpoint for
all experiments was 72 h
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cybrids treated with HNG plus amyloid-β1–42 (bar 5) showed
107.7% increased cell viability compared to amyloid-β1–42-
treated-AMD cybrids (Po0.001, bar 2) ( Supplementary Table
10 B). Our findings demonstrate that HNG was protective in
AMD cybrids treated with amyloid-β1–42 (active form).
HNG prevents loss of AMD mitochondria. Confocal
microscopy of AMD cybrids stained with CellLight mtGFP
fluorescent probe for 48 h showed higher levels of mitochon-
dria in HNG-treated AMD cybrids (Figures 8a and b).
Significant increase in fluorescent intensity (194.3%,
Po0.001) was observed in HNG-treated AMD cybrids
compared to untreated-AMD cybrids. No difference was
observed between untreated-normal and HNG-treated
normal cybrids (Supplementary Table S11). This finding
indicates that HNG can increase mitochondria-targeted
staining in AMD cybrids.
Discussion
In the current study, we used the transmitochondrial ARPE-19
cybrid model to identify and characterize the effects of AMD
mitochondria on human retinal cells. Through a combination of
cell-based and molecular biology assays, we found that
cellular/mitochondrial damage occurred at multiple levels in
AMD cybrids, and that HNG protected AMD cybrids from
mtDNA mediated and amyloid-β-induced cellular stress.
Previous studies have shown that mtDNA-deficient (Rho0)
ARPE-19 cells had diminished mitochondrial membrane
potential, altered expression of genes related to lipid transport,
inflammation, drusen deposits and various extracellular matrix
materials compared to wild-type cells.30 This indicates that the
mitochondria play a role in those particular pathways. The
present study used these same Rho0 ARPE-19 cells as the
host cell to create the cybrids using mitochondria from either
AMD or age-matched normal subjects. While the preparation
of Rho0 cells may affect the nuclear (n) DNA, the cell has
efficient, rapid nDNA repair mechanisms which the mtDNA
lacks.With the introduction of the AMDor normal mitochondria
into the uniform Rho0 ARPE-19 cell line, one can assume that
alterations in molecular or biochemical behavior seen in the
cybrids are due to the variations of the mtDNA rather than
nDNA. To test consistency, we have created different cybrid
batches using mitochondria from the same subject and the
gene expression patterns, cell viability and membrane
potentials were similar in the cell lines for the individuals.
Figure 5 HNG downregulates expression of apoptosis genes in AMD cybrids as measured by qRT-PCR: In AMD cybrids, HNG significantly decreased the expression of
apoptotic genes; BAX (49.4%, P= 0.002, n= 3–5; a), BCL2L13 (23.69%, P= 0.004, n= 4; b), Caspase-3 (25.85%, P= 0.004, n= 3; c), Caspase-7 (39.83%, P= 0.001, n= 3–
4; d), Caspase-9 (29.94%, P= 0.001, n= 3–4; e), compared to untreated (UN)-AMD cybrids (Supplementary Table S8). Data are represented as mean± S.E.M., normalized to
untreated-normal cybrids (assigned value of 1). The endpoint for all experiments was 72 h
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Therefore, our cybrid model represents a ‘personalized’model
that is reliable and uniform for each subject and can be used to
screen mitochondria-targeting drugs. Furthermore, the addi-
tional significant changes in cell-death related genes observed
in AMD cybrids could be attributed to unhealthy AMD
mitochondria.
AMD pathology is characterized by RPE cell death, which
precedes geographic atrophy and leads to eventual deteriora-
tion of the overlying photoreceptors.31 In addition, RPE cell
death induced by various stressors such as hydrogen
peroxide (tBHP), BMP4, and hypoxia has been demonstrated
in in vitro AMD models,32–34 and in several retinal degenera-
tion animal models.35,36 Consistent with those findings, our
results with Trypan blue and MTT cell viability assays
demonstrated substantial increase in AMD cybrid cell death
at 24h, 48h, and 72 h time points. Since all cybrids contained
similar nuclei and differed only in mtDNA, these results
indicated that mitochondria from AMD patients were dysfunc-
tional and mediated cell death. RPE cells are highly
metabolically active and contain large numbers of mitochon-
dria, which are the primary source of endogenous ROS.37 Our
results revealed that AMD cybrids have: (1) elevated levels of
mitochondrial superoxides, the predominant ROS found in the
mitochondria, and (2) reduced expression of antioxidant
genes, PRDX3 and SOD2. Together these data represent
an imbalance between mitochondrial ROS production and
antioxidant enzyme levels, which would lead to significantly
higher oxidative stress within AMD cybrids compared to the
controls. Our results are consistent with previous studies
showing that damaged mitochondria and ageing lead to
increased ROS and oxidative damage and reduced antiox-
idant capacity both in in vitro and in vivo models of retinal
diseases.38,39
Analyses of transcript profiles indicated that cybrids with
mitochondria from AMD subjects have higher levels of
apoptosis, autophagy and ER stress compared to cells
possessing normal mitochondria, suggesting that the
mechanism of cell death mediated by AMD mitochondria is
multifactorial. Our recent study also showed AMD mitochon-
dria altered the expression of complement pathwaymarkers in
AMD cybrids.28 It seems clear that damaged, unhealthy AMD
mitochondria transmit retrograde signals to mediate expres-
sion patterns of nuclear-encoded genes in cybrids but the
exact mechanisms are not yet known. Possible pathways
include changes in epigenetics mediated by mtDNA
variants,29,40,41 and mtDNA fragments that upregulate inflam-
matory genes’ expression, via the STING (Stimulator of
Interferon Genes) pathway.42 To cope with perturbations in
cellular homeostasis within retinal cells, apoptosis, unfolded
protein response due to ER stress, and autophagy are
triggered.43–45 Additionally, apoptosis- and ER stress-
mediated cell death of RPE has been documented in various
retinal layers in retinal degenerative diseases, including
AMD.46,47 However, to our knowledge, ours is the first study
demonstrating that platelet-derived mitochondria from AMD
Figure 6 HNG effects via intracellular (BAX) and extracellular pathways (gp 130 and phospho-JAK2) in AMD and normal cybrids as shown by western blot analyses: BAX
protein levels were 145.9% higher (P= 0.04, n= 3–5) in untreated (UN)-AMD cybrids than untreated (UN)-normal (NL) cybrids (a). HNG-treated AMD cybrids had lower BAX
protein levels (74.42%, P= 0.002, n= 3–5) compared to untreated-AMD cybrids (a). Untreated-AMD cybrids showed 44.4% lower gp130 protein levels compared to untreated-
normal cybrids (P= 0.03, n= 3–4; b). HNG-treated AMD cybrids had 61.87% increased levels of gp130 protein compared to untreated-AMD cybrids (P= 0.007, n= 3–4; b)
Phospho-JAK2 protein levels were 20.3% lower in untreated-AMD cybrids compared to untreated-normal cybrids (P= 0.009, n= 4; c). HNG-treated AMD cybrids showed
48.05% higher phospho-JAK2 protein levels than untreated-AMD cybrids (P= 0.003, n= 4; c) (Supplementary Table S9). Data are represented as mean±S.E.M., normalized to
untreated-normal cybrids (assigned value of 1). The endpoint for all experiments was 72 h
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Figure 7 HNG reduces amyloid β-induced and mtDNA-mediated cell stress: Protective effects of pre-treatment with HNG against amyloid-β cytotoxicity were measured using
the MTTassay. Amy-β Active (1-42) represents Amyloid-β1–42 which is the active form; Amy-β SC(42-1) represents amyloid-β42-1 which is the scrambled, inactive form that serves
as control. (a) Compared to untreated (UN)-normal (NL) cybrids, Amy-β Active (1-42)-treated NL cybrids showed a 35% (Po0.001, n= 4) reduction in cell viability. No
differences in cell viability were observed between untreated-NL cybrids and Amy-β SC(42-1)-treated NL or HNG-treated NL. Cell viability was significantly higher (31.25%,
Po0.05, n= 4) for Amy-β SC(42-1)-treated NL cybrids versus Amy-β Active (1-42)-treated NL cybrids. HNG increased cell viability by 35.94% (Po0.05, n= 4) in Amy-β Active
(1-42)-treated NL cybrids compared to the NL cybrids treated with Amy-β Active (1-42)-treated alone (Supplementary Table S10A). (b) Treatment of AMD cybrids with Amy-β
Active (1-42) alone reduced cell viability by 41.8% (Po0.05, n= 3–4) compared to untreated-AMD cybrids. No difference in cell viability was observed between untreated-AMD
cybrids and Amy-β SC(42-1)-treated AMD cybrids. Significant reduction in cell viability was observed in Amy-β Active (1-42)-treated AMD cybrids (94.9%, Po0.01, n= 3–4)
compared to the Amy-β SC(42-1)-treated AMD cybrids. AMD cybrids treated with HNG alone had a 42.4% increase in cell viability compared to untreated-AMD cybrids (Po0.05,
n= 3–4). Pre-treatment with HNG increased cell viability by 107.7% in Amy-β Active (1-42)-treated AMD cybrids (Po0.001, n= 3–4) compared to the AMD cybrids treated with
active Amy-β Active (1-42) alone (Supplementary Table S10B). Data are represented as mean± S.E.M., normalized to untreated-normal cybrids (assigned value of 1). The
endpoint for all experiments was 72 h
Figure 8 HNG prevents loss of AMD mitochondria: (a) Confocal images of cybrids treated with mtGFP stain demonstrated increased mtGFP fluorescence in HNG-treated
AMD cybrids. (b) In AMD cybrids, quantification graphs show that HNG increases mtGFP fluorescence by 194.3% (Po0.001, n= 5) compared to AMD cybrids. The HNG-treated
normal cybrids and untreated-normal cybrids showed similar levels of mtGFP staining (Supplementary Table S11). Scale bar= 20 μm. Data are represented as mean±S.E.M.,
normalized to untreated-normal cybrids (assigned value of 1). The endpoint for all experiments was 72 h
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patients can significantly alter cell survival, reflecting similar
events that occur in the AMD retinas.
Feher et al. used morphometric analyses of transmission
electron micrographs to show that mitochondria of human
primary RPE cells from AMD eyes were decreased in number
and size, had disrupted cristae, disrupted mitochondrial
membranes, and extensive reduction in matrix density
compared to the controls.48 In our study, multiple techniques
were used to demonstrate that AMD mitochondria are
damaged compared to age-matched normal. AMD cybrids
exhibited a significant decrease in mitochondrial GFP fluor-
escence, lower mtDNA copy numbers and increased mtDNA
fragmentation compared to normal cybrids. Furthermore,
AMD cybrids had downregulation of TFAM, POLG, POLRMT,
and TFB2M genes, suggesting impaired mitochondrial tran-
scription/replication. Cytoprotective MDPs, such as Humanin
and SHLPs, are encoded in the mitochondrial genome at the
16S rRNA gene.15 Real-time PCR with primers spanning
503–2484 bps mtDNA regions showed increased numbers of
mtDNA lesions in this region of the AMD mitochondrial
genome. Our results are consistent with Ferrington et al.’s
that demonstrated elevated levels of mtDNA lesions in specific
regions, including MDP-coding regions of the mitochondrial
genome, in AMD primary human RPE cells.49 Other studies
have also established a link between human RPE mtDNA
damage and pathologic ageing in AMD.7 It may be that mtDNA
fragmentation disrupts the integrity of mitochondria and the
threshold levels of MDPs essential for maintaining mitochon-
drial/cellular health and longevity.
In order to rescue and restore homeostasis to cells, we
hypothesized that cellular and mitochondrial damage
observed in AMD cybrids could be prevented by treatment
with HNG, amore potent variant of Humanin. To that end, AMD
and normal cybrids were treated with 3.2 μM HNG, co-stained
with YO-PRO1/Propidium iodide and the apoptotic cell
percentage measured using flow cytometry. As predicted,
treatment of AMD cybrids with HNG led to a drastic decrease
in numbers of apoptotic cells, confirming that HNG protected
AMD cybrids against mitochondria-mediated cell death.
These results are similar to Hinton et al.’s study showing
Humanin was capable of protecting primary human RPE cells
against oxidative stress-induced and ER stress-induced cell
death,24 using tert-Butyl hydroperoxide and tunicamycin,
respectively.
Having confirmed the cytoprotective role of HNG on
quiescent cybrids containing AMD mitochondria, we next
determined the effects of HNG on cybrids stressed by
exposure to amyloid-β peptides. Significant cytotoxicity was
demonstrated in normal and AMD cybrids exposed to the
active amyloid-β1-42 peptide. However, pretreatment with HNG
protected both AMD and normal cybrids from amyloid-β1-42-
induced toxicity. These findings are significant because
amyloid-β is a key constituent of drusen, which are sub-RPE
deposits composed primarily of lipid and proteins.50 Previous
studies have demonstrated that cleavage of APP (amyloid
precursor protein) by proteases produces the long forms of
amyloid-β (i.e.,amyloid-β42) which are fibrillogenic, plaque-
forming and associated with neurodegenerative disease
states, including Alzheimer’s disease.51,52 Our findings agree
with studies reporting the cytoprotective roles of Humanin and
HNGagainst amyloid-β-induced cell death in numerous aging-
related diseases.53 For instance, Hashimoto et al. demon-
strated that Humanin inhibits neuronal cell death induced by
amyloid-β, mutant APP, and presenilin.54,55 Zhang et al.
showed that administration of HNG attenuates neuro-inflam-
mation, cognitive deficits, and amyloid-β burden in a trans-
genic mousemodel of Alzheimer’s disease.56 Humanin and/or
HNG have also been shown to offer protection in cardiovas-
cular, metabolic, inflammation, and cancer disease
models.20,57,58
One mechanism by which HNG protects AMD cybrid cells
from death may be through stabilization of mitochondria and
prevention of mitochondrial death. HNG-treated AMD cybrids
had 197.1% increase in mtGFP fluorescence compared to
untreated-AMD cybrids, demonstrating that the AMD mito-
chondria can be rescued by HNG pretreatment. This finding
agrees with a previous study showing Humanin protects
mitochondria in primary RPE cells.24
Next, we investigated the mechanisms by which HNG
exerts its cytoprotective effects. Humanin affects cells via both
intracellular and extracellular mechanisms.13 Humanin can
bind BAX protein, which prevents the coupling of tBid with
BAX, and the release of cytochrome c, thereby inhibiting
apoptosis.59 In untreated-AMD cybrids, the BAX protein levels
were significantly elevated by 146% but declined drastically by
74% after HNG treatment. These findings indicate that HNG
exerts its cytoprotective action via the intracellular mechanism
involving BAX protein. With respect to the extracellular
mechanism, Humanin is known to bind to a trimeric CNTFR/
gp130/WSX-1 receptor complex, inducing activation of
JAK-STAT pathway and transcription of downstream
genes.60 In the current study, untreated-AMD cybrids had
significantly reduced gp130 protein compared to untreated-
normal. However, addition of HNG led to 61.87% increase in
gp130 protein levels compared to untreated-AMD cybrids,
thus restoring levels to that seen in normal cybrids. This
suggests that AMD cybrids may have either a low abundance
of the trimeric receptor or perhaps a faulty receptor complex
which does not allow Humanin to bind and exert its
cytoprotective effects. We speculate that gp130 and the
trimeric receptor complex is associated with HNG-induced
rescue of AMD cybrids. Furthermore, the initially low levels of
phospho-JAK2 protein were restored with HNG in normal and
AMD cybrids, suggesting that restoring gp130 levels may
mediate activation of JAK and promotes cytoprotective effects.
To conclude, this novel study demonstrates that mitochon-
dria from AMD patients are severely damaged, and highlights
the protective role of HNG against mitochondria-mediated and
amyloid-β-induced cell death in AMD transmitochondrial
ARPE-19 cybrids. Our findings support the hypothesis that
HNG is a significant cell survival factor and should be
considered as a potential therapy for the treatment of dry
AMD. These results also highlight the potential beneficial
properties of Humanin and other MDPs that have been
characterized in non-ocular disease models but have not yet
been investigated in AMD and other age-related eye diseases.
Materials and Methods
Human subjects. Research involving human participants was approved by the
Institutional review board of the University of California, Irvine (#2003-3131). Written
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informed consent was obtained from all subjects (Supplementary Table S1) and
clinical investigations were conducted according to the tenets of Declaration of
Helsinki for research involving human subjects. We found no significant difference
(P= 0.07) in ages of normal (72.60± 1.7 years) and AMD (77.60± 1.6 years)
subjects (N= 5).
Transmitochondrial cybrids. Transmitochondrial cybrids were created by
fusing mitochondrial DNA-deficient APRE-19 (Rho0) cell line with platelets isolated
from either AMD patients or age-matched normal subjects. Peripheral blood (10 ml)
was collected via venipuncture in tubes containing 10 mM EDTA. Blood platelets
were isolated by a series of centrifugation steps, in tubes containing 3.2% sodium
citrate, and final pellets were suspended in Tris buffered saline. To create the
ARPE-19 Rho0 cells, ARPE-19 cells were serially passaged into medium containing
50 ng/ml ethidium bromide.30 Cybrids were created by polyethylene glycol fusion of
platelets with Rho0 ARPE-19 cells in medium containing uridine. After growing the
cybrid cells in uridine-containing medium for 2 weeks, the medium was replaced
with regular culture medium. Mitochondrial DNA haplogroups profiles of each cybrid
were confirmed using PCR, restriction enzyme digestion, and sequencing. The
SNPs defining the H haplogroup were T7028C and G73A. All transmitochondrial
cybrids were grown in DMEM/Ham’s F12 1:1 (Invitrogen-Gibco, Gaithersburg, MD,
USA) cell culture medium containing 24 mM sodium bicarbonate, 10% dialyzed fetal
bovine serum, and 1.0 mM sodium pyruvate. Passage 5 cybrids were used for all
experiments. Age-matched normal cybrids served as controls.
Treatment with Humanin G (HNG). Lyophilized HNG (Anaspec, Fremont,
CA, USA) was reconstituted in water to obtain a stock solution that was
subsequently dissolved in culture media to obtain a 3.2 μM HNG working solution.
In this study, all cybrids were treated with 3.2 μM HNG. At the beginning of this
study we tested a wide range of concentrations (based on the published Humanin
literature) ranging from 0.8 to 10 μM to determine a low optimum working
concentration of HNG in our ARPE-19 cybrid cells. The HNG concentrations of 0.8
and 1.6 μM did not show any protective effects. Our preliminary studies
demonstrated that 3.2 μM was the lowest concentration that showed significant
protective effects in the cybrid cells. Therefore, we used 3.2 μM as our final working
concentration for all experiments with HNG.
MTTassay. The MTTassay is a colorimetric test that utilizes the phenomenon of
reduction of tetrazolium salts to measure cell viability. Healthy actively metabolizing
cells contain NAD(P)H-dependent cellular oxidoreductase enzymes that reflect the
number of viable cells present. These enzymes reduce the water-soluble yellow
tetrazolium dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
to its insoluble formazan, which has a purple color. The formazan crystals are then
solubilized by adding dimethyl sulfoxide (DMSO) and the colorimetric signal, which
is proportional to the number of viable cells, is determined by measurement of
optical density at 570 nm. MTT assays were performed in the dark since the MTT
reagent is sensitive to light.
AMD and normal cybrids (n= 4-5) plated in 96-well tissue culture plates were
treated with MTT solution (Cat.# 30006, Biotium, Fremont, CA, USA) at 24, 48, 72,
and 96 h time points. MTT-treated cells were incubated at 37 °C for 1 h, followed by
addition of DMSO. Absorbance was measured on a spectrophotometer at 570 nm
and background absorbance measured at 630 nm. Background absorbance was
subtracted from signal absorbance to obtain normalized absorbance values. The
colorimetric signal obtained was proportional to the cell number.
Trypan Blue dye exclusion assay. Trypan blue is a diazo dye that
selectively stains dead cells blue. Trypan blue dye exclusion test is based on the
principle that live cells that have intact cell membranes are impervious to Trypan
blue dye; therefore viable cells are excluded from staining blue. Since in our study,
cell growth of cybrids peaked at 72 h, AMD and normal cybrids (n= 5) were plated
in six-well plates, trypsinized at 72 h, and transferred to a counting vial. Cell count in
each sample was determined using a cell counter (ViCell, Beckman Coulter, Brea,
CA, USA) that uses Trypan blue dye to determine the number of viable cells. A total
of 50 images were captured and averaged per sample.
MitoSOX assay. The MitoSOX Red reagent is a live-cell permeant fluorogenic
dye that allows highly selective detection of mitochondrial superoxides in live cells.
Once the MitoSOX Red reagent is oxidized by superoxides, it exhibits red
fluorescence that can be quantified. AMD and normal cybrids (n= 5) were plated in
24-well tissue culture plates for 72 h. The 5 mM MitoSOX reagent (Cat.# M36008,
Invitrogen, Grand Island, NY, USA) stock solution was diluted with HBSS (Hank’s
balanced salt solution) buffer to make a 5 μM MitoSOX reagent working solution.
Cells were treated with 5 μM MitoSOX reagent and incubated for 10 min at 37 °C.
Cells were then washed with HBSS buffer, and fluorescence was measured at
excitation/emission maxima of 510/580 nm.
Confocal microscopy. To estimate the number of mitochondria in normal
and AMD cybrid cells, CellLight mtGFP staining was performed. The CellLight
Mitochondrial GFP stain (Cat. # C10582, Thermo Fisher Scientific, Waltham, MA,
USA) is a baculovirus fusion construct having a mammalian promoter and a leader
sequence of E1 alpha pyruvate dehydrogenase fused to GFP. Therefore, it
specifically targets mitochondria and mtGFP fluorescence can be quantified. Normal
and AMD cybrids (n= 5) were plated in four-well tissue culture chamber slides for
72 h. At 48 h, CellLight stain was added to the medium at a concentration based on
the cell density at the end of incubation period. The cells in chamber slides were
incubated overnight at 37 °C. The cells were washed with 1 × TBS (Tris-buffered
saline), fixed in paraformaldehyde, washed again with 1 × TBS, mounted in DAPI,
coverslipped, and stored at 4 °C. Confocal z-stack images were captured using the
LSM-700 Confocal microscope (Zeiss, Thornwood, NY, USA). All confocal images
were quantified using the inbuilt ZEN 2 lite software.
Mitochondrial copy number. Normal and AMD cybrids (n= 5) were grown
in six-well plates, and total DNA was isolated at 72 h after plating. Quantitative real-
time PCR was performed using TaqMan gene expression assays for 18S and MT-
ND2 (Cat. # 4331182, Thermo Fisher Scientific) genes and TaqMan gene
expression master mix (Cat. # 4369016, Thermo Fisher Scientific). Relative mtDNA
copy numbers were determined using delta Cts. All samples were run in triplicates.
Mitochondrial DNA fragmentation assay. To examine mitochondrial
lesions in cybrid DNA, real-time PCR was performed with total DNA isolated at 72 h
from normal (n= 5) and AMD cybrids (n= 5) using primers covering the MT-12S
and MT-16S region of the mtDNA (Forward primer: 5′-ATCCTACCCAGCACAC
AC-3′; Reverse primer: 5′-GATTTGCCGAGTTCCTTTTACT)-3′, and the Accuprime
TaqMan DNA Polymerase System (Cat. # 12339016, Thermo Fisher Scientific).
PCR products were run on 1% agarose gels and imaged under UV light. Number of
mtDNA lesions were counted and compared between normal and AMD groups.
Quantitative real-time PCR (qRT-PCR). RNA extraction and cDNA
synthesis: Normal and AMD cybrid cells (n= 5) were grown in six-well plates, and
RNA was extracted at 72 h using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
as per the manufacturer’s protocol. The extracted RNA was quantified using
NanoDrop 1000 Spectrophotometer (Thermoscientific, Waltham, MA, USA). RNA
(100 ng/μl) was reverse transcribed into cDNA using Superscript VILO Master Mix
(Cat. # 11755-050, Invitrogen). Diluted cDNA was stored at –20 °C until used.
qRT-PCR. qRT-PCR was performed using StepOnePlus Real-Time PCR system
(Applied Biosystems, Carlsbad, CA, USA) to study the expression of apoptosis,
autophagy, ER stress, and antioxidant genes. Each sample was run in triplicate. The
QuantiTect Primer Assays (Qiagen) (Supplementary Table S2) and Power SYBR
Green PCR Master Mix (Cat. # 4367659, Life Technologies, Grand Island, NY, USA)
were used. Specific housekeeper genes used are listed in Supplementary Table S2.
qRT-PCR data were analyzed using ΔΔCt method. ΔCt was the difference
between the Cts (threshold cycles) of the target gene and Cts of the housekeeper
gene (reference gene). ΔΔCt was calculated by subtracting ΔCt of the AMD group
from ΔCt of the normal group. Fold change was calculated using the following
formula: Fold change = 2ΔΔCt.
Western blotting analyses
Protein extraction: Normal and AMD cybrid cells (n= 3–5) were plated in six-
well plates for 72 h. Cells were lysed using RIPA buffer (Cat. # 89900, Life
Technologies), supernatants transferred to a new microfuge tube and concentrations
of proteins were measured using Bio-Rad Dc protein assay system (Bio-Rad
Laboratories, Richmond, CA, USA) according to the manufacturer's instructions.
Immunoblotting: Equal concentrations of total protein samples were loaded into
the wells of 4–12% Bolt mini gels (Life Technologies) followed by SDS-PAGE
electrophoresis. The gels were then transferred onto PVDF membranes. Following
transfer, the membranes were blocked in 5% milk for 1 h, then incubated overnight
at 4oC in primary antibodies (Supplementary Table S3). Blots were then washed
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with 1 × TBST (Tris Buffered Saline-Tween20) and incubated with the respective
secondary antibodies for 1 h at room temperature. All primary and secondary
antibodies were diluted in 1 × TBST. Following secondary antibody incubation, the
blots were washed with 1 × TBST. Protein bands were detected using Clarity
Western ECL Blotting Substrate (Cat. #1705060, Bio-Rad). β-actin antibody was
used as a housekeeper protein control. Protein bands were visualized using
Versadoc imager (Bio-Rad), and quantified using ImageJ software (NIH Image).
Flow cytometry. Normal and AMD cybrids (n= 4–5) were stained with
YOPRO-1/propidium iodide (PI) (Cat. # V13243, Invitrogen), and incubated on ice
for 20–30 min. Following incubation, stained cells were analyzed by flow cytometry,
using 488 nm excitation with green fluorescence emission for YOPRO-1 (i.e., 530/30
bandpass) and red fluorescence emission for PI (i.e., 610/20 bandpass), gating on
cells to exclude debris. Standard compensation analysis using single-color stained
cells was performed. The YO-PRO-1 dye (green fluorescent) can enter apoptotic
cells, whereas PI (red fluorescent dye) cannot. Therefore, YO-PRO-1 dye and PI
together provide a sensitive indicator for apoptosis. Live cells show a low level of
green fluorescence, apoptotic cells show an incrementally higher level of green
fluorescence, and dead cells show both red and green fluorescence.
Treatment with amyloid-β peptides. Lyophilized amyloid-β1–42 (active
form) (Cat. # AS-20276, Anaspec) and amyloid-β42–1 (inactive scrambled control)
peptides (Cat. # 27276, Anaspec) were reconstituted in 1% ammonium hydroxide to
prepare a stock solution, that was subsequently dissolved in 1 × PBS (phosphate-
buffered saline) to obtain a 20 μM working solution. All cybrids (n= 4–5) were
treated for 24 h with 20 μM amyloid-β peptides in this study.
Statistical analysis. Results between groups were analyzed for differences
using the unpaired Student’s t-test or one-way ANOVA followed by Tukey–Kramer
post-hoc test (GraphPad Prism 5.0; GraphPad Software, CA, USA). Statistical
significance was determined at P-values o0.05.
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